- Home
- CVGW vs CELC Comparison
CVGW vs CELC Comparison
Compare CVGW & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVGW
- CELC
- Stock Information
- Founded
- CVGW 1924
- CELC 2011
- Country
- CVGW United States
- CELC United States
- Employees
- CVGW N/A
- CELC N/A
- Industry
- CVGW Specialty Foods
- CELC Medical Specialities
- Sector
- CVGW Consumer Discretionary
- CELC Health Care
- Exchange
- CVGW Nasdaq
- CELC Nasdaq
- Market Cap
- CVGW 429.3M
- CELC 391.0M
- IPO Year
- CVGW N/A
- CELC 2017
- Fundamental
- Price
- CVGW $24.09
- CELC $9.29
- Analyst Decision
- CVGW Strong Buy
- CELC Strong Buy
- Analyst Count
- CVGW 1
- CELC 6
- Target Price
- CVGW $35.00
- CELC $30.17
- AVG Volume (30 Days)
- CVGW 198.6K
- CELC 260.9K
- Earning Date
- CVGW 03-12-2025
- CELC 05-14-2025
- Dividend Yield
- CVGW 3.32%
- CELC N/A
- EPS Growth
- CVGW N/A
- CELC N/A
- EPS
- CVGW 0.54
- CELC N/A
- Revenue
- CVGW $688,323,000.00
- CELC N/A
- Revenue This Year
- CVGW $8.03
- CELC N/A
- Revenue Next Year
- CVGW $8.09
- CELC N/A
- P/E Ratio
- CVGW $30.97
- CELC N/A
- Revenue Growth
- CVGW 16.87
- CELC N/A
- 52 Week Low
- CVGW $20.30
- CELC $8.50
- 52 Week High
- CVGW $30.58
- CELC $20.89
- Technical
- Relative Strength Index (RSI)
- CVGW 51.33
- CELC 35.82
- Support Level
- CVGW $23.30
- CELC $9.98
- Resistance Level
- CVGW $24.60
- CELC $10.91
- Average True Range (ATR)
- CVGW 0.80
- CELC 0.74
- MACD
- CVGW 0.07
- CELC -0.01
- Stochastic Oscillator
- CVGW 63.33
- CELC 29.59
About CVGW Calavo Growers Inc.
Calavo Growers Inc is in the avocado industry and an expanding provider of value-added fresh food. The company distributes its products both domestically and internationally and reports its operations in two different business segments: Grown and Prepared. The Grown segment consists of fresh avocados, tomatoes, and papayas. The Prepared segment comprises all other products including fresh-cut fruits and vegetables, ready-to-eat sandwiches, wraps, salads and snacks, guacamole, and salsa sold at retail and food service as well as avocado pulp sold to food service.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.